External Advisory Board

Grand MMTI –  External Advisory Board

The Grand MMTI's External Advisory Board (EAB) consists of internationally recognized myeloma clinicians and researchers. The SAB provides scientific and strategic guidance on the Grand MMTI clinical and research programs and provides insights on the most up-to-date advances in the treatment and diagnosis of multiple myeloma.

Constantine Mitsiades, MD, PhD
Instructor, Department of Medicine, Harvard Medical School
Instructor in Medicine, Medical Oncology, Dana-Farber Cancer Institute

Dr. Constantine Mitsiades is a physician/scientist at Dana-Farber Cancer Institute in which his research has led to the clinical development of novel therapeutics, including the FDA approved combination of proteasome inhibitors with anthracyclines. He has many years of experience in the field of multiple myleoma and the role of the tumor microenvironment.

Sagar Lonial, MD, PhD
Professor of Hematology/Oncology, Winship Cancer Institute, Emory University
Director of Translational Research B-cell Malignancy Program
Vice Chair of Clinical Affairs Hematology & Medical Oncology

Dr. Sagar Lonial is a Professor at the Winship Cancer Institute of Emory University, and is also Director of Translational Research, B-cell malignancy program. He is on staff and works both on the bone marrow transplant service as well as in the B-cell malignancy clinic. Dr. Lonial completed his Hematology-Oncology training at Emory University, and prior to that received his Internal Medicine residency at the Baylor College of Medicine in Houston, Texas. There he spent an additional year as a Chief Medical Resident at the Ben Taub General Hospital as well as the Texas Heart® Institute and St. Luke’s Episcopal Hospital. Dr. Lonial has worked in the field of immunotherapy and cancer since his arrival at Emory, and in previous years has spent time developing the B-cell malignancy program with respect to novel targeted agents in laboratory models as well as early clinical trials. Dr. Lonial’s laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen. Most recently, Dr. Lonial has focused on combinations of novel agents as therapy for myeloma and lymphoma, and his lab has recently received funding from the MMRF. Dr. Lonial has received the Lymphoma Research Foundation’s Clinical Investigator Award as well as support from the V-Foundation and the American Cancer Society. He is an ad hoc reviewer for Blood, Cancer Research, and other journals, and has authored or coauthored over 30 papers and abstracts.

Mark Rolfe, PhD
President and CSO, Cleave Biosciences
Dr. Mark Rolfe has over 20 years of industry experience in oncology drug discovery and development and is a recognized expert in the field of protein homeostasis. Before joining Cleave Biosciences, he spent a year at CytomX Therapeutics as Chief Scientific Officer and a year at Facet Biotech in the same role as well as interim Chief Medical Officer until its successful acquisition by Abbott Laboratories. Prior to joining Facet, Dr. Rolfe served as Vice President, Oncology Discovery at Millennium Pharmaceuticals where his group progressed multiple novel drugs targeting protein homeostasis into development. At Millennium he also spent two years as the VELCADE® Discovery Leader, during which time the drug received a number of regulatory approvals. Prior experience includes research positions at Mitotix Inc. and Celltech Ltd.

Sergio Giralt, MD
Chief, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering
Dr. Sergio Giralt is an internationally recognized bone marrow transplantation expert. In 2010, he joined the Memorial Sloan-Kettering Cancer Center as Chief of the Adult Bone Marrow Transplant Service, following a 20-year-long career at the MD Anderson Cancer Center. Dr. Giralt received his medical degree from Universidad Central de Venezuela in Caracas, Venezuela, and completed his postgraduate internship at the University Hospital of Caracas.

Board certified in internal medicine, hematology, and medical oncology, Dr. Giralt’s research focuses on improving treatments for older patients, particularly in the area of stem cell transplant. He holds key positions with several transplant organizations, including the International Bone Marrow Transplant Registry Executive Committee, the Blood and Marrow Transplant Clinical Trials Network (BMTCTN) Steering Committee, the National Marrow Donor Program Board of Directors, and the Clinical Advisory Board of the website Managing Myeloma. He is the chair of the BMTCTN and past chair of Center for International Blood and Marrow Transplant Research. Dr. Giralt has published over 400 articles and abstracts in peer-reviewed literature and has written chapters for several books.